Biofourmis vs Harrison.ai

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Biofourmis employs 100-500 people, while Harrison.ai has 100-500 employees.

Biofourmis has raised more in total funding at $445M, compared to Harrison.ai's $129M — a gap of $316M.

Biofourmis holds the higher Awaira Score at 73/100, compared to Harrison.ai's 68/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 5-point gap that reflects meaningful differences in scale or traction.

Biofourmis was founded by Kuldeep Singh in 2015. Harrison.ai was founded by Aengus Tran in 2018. Visit each company's profile on Awaira for a full founder biography.

Biofourmis: Biofourmis develops AI-powered digital therapeutics and remote patient monitoring technology that combines wearable biosensor data with machine learning models to predict clinical deterioration, monitor chronic disease progression, and support clinical trial digital endpoint measurement. The Singapore company platform processes continuous physiological data streams from patients in hospital-at-home programs, enabling earlier clinical intervention and reducing avoidable readmissions for heart failure, oncology, and post-surgical patients.\n\nThe company raised approximately $445 million including a Series D from investors including SoftBank Vision Fund 2, Openspace Ventures, and Mass General Brigham Ventures. Biofourmis has built partnerships with health systems including Brigham and Women Hospital, Guy Hospital, and several major Asian health systems for remote monitoring program deployment, and has entered into pharmaceutical partnerships for using its digital monitoring platform as a clinical trial measurement tool to capture digital endpoints.\n\nBiofourmis competes in the remote patient monitoring and digital therapeutics market against BioIntelliSense, Current Health, and Validic, as well as the monitoring capabilities of established medical device companies including Philips and Masimo that are adding AI analytics to their remote monitoring platforms. The hospital-at-home model, which uses continuous remote monitoring AI to substitute inpatient hospital stays for selected patient populations, represents a significant healthcare cost reduction opportunity that health systems in the US, UK, and Asia are actively piloting. Harrison.ai: Harrison.ai develops AI radiology and pathology analysis software for clinical deployment, building FDA-cleared and TGA-registered algorithms for chest X-ray abnormality detection, CT pulmonary angiography analysis, and mammography screening under its Annalise.ai product brand. The Sydney company focuses on AI clinical decision support that helps radiologists prioritise worklists, detect abnormalities, and reduce reporting errors in high-volume radiology departments.\n\nThe company raised approximately $129 million including a Series C from investors including Blackbird Ventures, Skip Capital, and Telstra Ventures. Harrison.ai has deployed its Annalise.ai platform across Australian hospital networks and has received US FDA clearance for its chest X-ray AI product, enabling international commercial expansion beyond Australia. The company has published clinical validation studies demonstrating AI performance that is non-inferior to specialist radiologist reads on chest X-ray abnormality detection across multiple institutions.\n\nHarrison.ai competes in the AI radiology market against Aidoc, Lunit, Qure.ai, and Behold.ai, which all target radiologist workflow assistance and clinical alerting. The Australian healthcare market provides a strong home base given the National Health Service framework and centrally coordinated radiology procurement, while FDA clearance opens the substantially larger US radiology AI market. The company is considered one of Australia most promising medical AI companies and a flagship for the Australian healthcare technology ecosystem.

Biofourmis was founded first in 2015, giving it 3 years of additional market experience. Harrison.ai was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Both Biofourmis and Harrison.ai report similar employee counts of approximately 100-500. Team size is often a proxy for operational scale, though lean AI companies can punch well above their headcount.

Yes, Biofourmis and Harrison.ai are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.